{"id":243076,"date":"2026-08-22T21:08:21","date_gmt":"2026-08-23T02:08:21","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/08\/first-in-class-therapy-targets-undruggable-protein-in-hard-to-treat-blood-cancers"},"modified":"2026-08-22T21:08:21","modified_gmt":"2026-08-23T02:08:21","slug":"first-in-class-therapy-targets-undruggable-protein-in-hard-to-treat-blood-cancers","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/08\/first-in-class-therapy-targets-undruggable-protein-in-hard-to-treat-blood-cancers","title":{"rendered":"First-in-class therapy targets \u2018undruggable\u2019 protein in hard-to-treat blood cancers"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/first-in-class-therapy-targets-undruggable-protein-in-hard-to-treat-blood-cancers2.jpg\"><\/a><\/p>\n<p>A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in <a href=\"https:\/\/ashpublications.org\/blood\/article-abstract\/doi\/10.1182\/blood.2025030170\/570175\/Dual-MYC-and-GSPT1-Protein-Degrader-for-MYC-Driven\" target=\"_blank\">Blood<\/a>.<\/p>\n<p>Researchers led by Michael Andreeff, M.D., Ph.D., professor, and Yuki Nishida, M.D., Ph.D., assistant professor, both of Leukemia, found that the experimental drug GT19630 interrupts a newly discovered cycle between MYC and GSPT1, resulting in strong anticancer activity in preclinical models of leukemia, lymphoma and multiple myeloma, including treatment-resistant and TP53-mutated disease.<\/p>\n<p>\u201cFor decades, scientists have struggled to develop therapies that successfully block MYC, leading many in the field to describe it as undruggable,\u201d Andreeff said. \u201cBy identifying a vulnerability in the relationship between MYC and GSPT1, we found a way to eliminate both proteins and disable a pathway many cancers depend on for survival.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood. Researchers led by Michael Andreeff, M.D., Ph.D., professor, and Yuki Nishida, M.D., Ph.D., assistant [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-243076","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/243076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=243076"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/243076\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=243076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=243076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=243076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}